CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Crohn's Disease
Conditions
Crohn's Disease, Ulcerative Colitis (Part 2 Only)
Trial Timeline
Sep 29, 2016 → Oct 2, 2019
NCT ID
NCT02883452About CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 is a phase 1 stage product being developed by Celltrion for Crohn's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02883452. Target conditions include Crohn's Disease, Ulcerative Colitis (Part 2 Only).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02883452 | Phase 1 | Completed |
| NCT03147248 | Phase 3 | Completed |
Competing Products
20 competing products in Crohn's Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CT-P13 + Remicade | Celltrion | Phase 3 | 77 |
| CT-P13 SC (Infliximab) | Celltrion | Phase 3 | 77 |
| CP-461 | Astellas Pharma | Phase 2 | 52 |
| E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kg | Eisai | Phase 1/2 | 41 |
| E6011 + Placebo | Eisai | Phase 2 | 52 |
| E6011 + Placebo | Eisai | Phase 1 | 33 |
| adalimumab + adalimumab + placebo | Eisai | Phase 2/3 | 65 |
| adalimumab | Eisai | Phase 2/3 | 65 |
| Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + Placebo | Eli Lilly | Phase 3 | 77 |
| Mirikizumab | Eli Lilly | Phase 3 | 77 |
| Mirikizumab + Mirikizumab + Tirzepatide + Placebo | Eli Lilly | Phase 3 | 77 |
| Mirikizumab + Placebo | Eli Lilly | Phase 2 | 52 |
| Mirikizumab | Eli Lilly | Phase 3 | 77 |
| Matching Placebo for Upadacitinib + Upadacitinib | AbbVie | Phase 3 | 77 |
| Adalimumab + Placebo | AbbVie | Phase 3 | 77 |
| Upadacitinib + Placebo for Upadacitinib | AbbVie | Phase 3 | 77 |
| Placebo + ABT-494 | AbbVie | Phase 2 | 52 |
| ABT-494 | AbbVie | Phase 2 | 52 |
| Risankizumab + Comparator | AbbVie | Pre-clinical | 23 |
| placebo for risankizumab + risankizumab IV + risankizumab SC | AbbVie | Phase 3 | 77 |
Other Products from Celltrion
Azathioprine + PlaceboApproved
85
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved
85
Infliximab + Infliximab + InfliximabApproved
85
Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved
85
Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved
85